After our scientists developed a very sensitive chemiluminescent sandwich EIA specific for inducible nitric oxide synthase (iNOS) based upon our patented monoclonal antibodies, we discovered iNOS was found exclusively in the plasma of patients with sepsis or who developed sepsis within the next 24 – 48 hours, and have conclusively demonstrated plasma iNOS can be used as a very specific biochemical marker for the onset of the sepsis pathology. To date, more than 340 subjects have been enrolled in clinical trials and more than 1,200 human plasma samples have been collected and analyzed. From the analysis of blood samples obtained from trauma patients in two different university medical center Intensive Care Units, our test for the new plasma biomarker iNOS was found to have a positive predictive value of greater than 96% and a specificity of greater than 92% for the hemodynamic, pulmonary and renal dysfunctions associated with the sepsis pathology. More recently our initial observation of plasma iNOS as a specific biomarker for the sepsis pathology has been confirmed by 3 different groups of academic biomedical researchers.

Our Discoveries

  • First to discover iNOS exclusively in plasma of septic patients
  • First to demonstrate plasma iNOS is an accurate biochemical marker that forecasts the onset of sepsis
  • First to demonstrate plasma iNOS is an accurate marker for monitoring the course of the sepsis pathology
  • First to demonstrate plasma iNOS is a new biomarker specific for the sepsis pathology

Lead to Unique Patented New Products

  • First in vitro diagnostic test to forecast accurately the onset of sepsis
  • Multiple issued patents
  • Notice of Allowance from the European Patent Office
  • Multiple pending patent applications

Open Unparalleled Business Opportunity

  • First to enter an untapped $850 million/year clinical IVD test market
  • USA market forecast to more than double in the next 20 years as the “Baby Boom” generation ages
  • Worldwide market forecast to increase significantly as China and India upgrade their national health care systems
Home | News | R&D Vision | President's Message | Achievements | Leadership Team | Technology | Contact